Partnology notes that Frontier Medicines is ramping up its ambitions after a tough stretch, advancing more cancer programs from its platform for undruggable targets.
Public source
Publisher name
Public post
A drug just cleared the FDA for one of the deadliest cancers there is, and it did it by hitting a target the industry spent decades calling impossible. Help amplify this…
Company
Partnology
Building Exciting Biotech Companies
- Industry
- Venture Capital and Private Equity Principals
- Location
- San Diego, US
- Company size
- 2–10 employees
About Partnology
Partnology is dedicated to the creation and nurturing of nascent biotech companies. Our strategy seamlessly links founders with aligned investors within the Venture Capital ecosystem. Not only do we actively participate in seed round investments, but when deemed beneficial, our executive search team recommends pivotal leadership figures, ensuring the dynamic progression of our partner companies.
See moreLatest activity
Latest activity from Partnology
10 signals
Capital & Finance
Partnology notes that AusperBio raised ~$120M in Series C financing to push its antisense therapy for chronic hepatitis B into Phase 3 and toward commercialization.
Capital & Finance
Partnology notes that Genentech licensed next-generation antibody-drug conjugates from China-based DualityBio for $45M upfront and up to $1B+ in milestones.
Capital & Finance
Partnology notes that Electra Therapeutics filed to go public, keeping 2026's IPO streak alive, with proceeds aimed at advancing its lead immunology antibody through Phase 2/3.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Frontier Medicines
Frontier Medicines CEO Chris Varma discussed progress over the years in pursuing targets previously considered undruggable, combining chemoproteomics, covalent chemistry, and AI.
Research & Knowledge
BioCentury Inc.
BioCentury Inc. published its annual Pharma Deal Analysis finding that deals by 21 top pharmaceuticals in the past 12 months are clustering in breakthrough new technologies.
Research & Knowledge
AlbionVC
AlbionVC highlights the T-cell engager modality as an elegant approach for immunotherapeutic treatment in both oncology and autoimmune disease.
Research & Knowledge
Drug Hunter
Drug Hunter spotlighted July 2026 molecules including ARTIOS PHARMA LIMITED’s ART6043, Eli Lilly and Company’s LY3410738, and Roche’s nivegacetor.
Research & Knowledge
Cancer Research Horizons